Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice by Liao, Birong et al.
Biomarker Insights 2008:3 147–157 147
ORIGINAL RESEARCH
Correspondence: Mark Rekhter, Atherosclerosis and Metabolic Syndrome Drug Hunting Team, Lilly Research 
Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Circulating Markers Reﬂ  ect Both Anti- and Pro-Atherogenic 
Drug Effects in ApoE-Deﬁ  cient Mice
Birong Liao
1, Eileen McCall
2, Karen Cox
1, Chung-Wein Lee
1, Shuguang Huang
3, 
Richard E Higgs
3, Li-Chun Chio
1, Eugene Zhen
1, John E Hale
1, Nancy K Jackson
2, 
Pamela G Rutherford
2, Xiao-di Huang
2, Donetta Gifford-Moore
2, Kwan Hui
2, 
Kevin Duffin
1, Kenneth E Gould
2 and Mark Rekhter
2
1Integrative Biology, 
2Atherosclerosis and Metabolic Syndrome Drug Hunting Team, 
3Discovery 
Statistics, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Abstract
Background: Current drug therapy of atherosclerosis is focused on treatment of major risk factors, e.g. hypercholesterolemia 
while in the future direct disease modiﬁ  cation might provide additional beneﬁ  ts. However, development of medicines tar-
geting vascular wall disease is complicated by the lack of reliable biomarkers. In this study, we took a novel approach to 
identify circulating biomarkers indicative of drug efﬁ  cacy by reducing the complexity of the in vivo system to the level 
where neither disease progression nor drug treatment was associated with the changes in plasma cholesterol.
Results: ApoE-/- mice were treated with an ACE inhibitor ramipril and HMG-CoA reductase inhibitor simvastatin. Ramipril 
signiﬁ  cantly reduced the size of atherosclerotic plaques in brachiocephalic arteries, however simvastatin paradoxically 
stimulated atherogenesis. Both effects occurred without changes in plasma cholesterol. Blood and vascular samples were 
obtained from the same animals. In the whole blood RNA samples, expression of MMP9, CD14 and IL-1RN reﬂ  ected pro-
and anti-atherogenic drug effects. In the plasma, several proteins, e.g. IL-1β, IL-18 and MMP9 followed similar trends while 
protein readout was less sensitive than RNA analysis.
Conclusion: In this study, we have identiﬁ  ed inﬂ  ammation-related whole blood RNA and plasma protein markers reﬂ  ecting 
anti-atherogenic effects of ramipril and pro-atherogenic effects of simwastatin in a mouse model of atherosclerosis. This 
opens an opportunity for early, non-invasive detection of direct drug effects on atherosclerotic plaques in complex in vivo 
systems.
Introduction
Current drug therapy of atherosclerosis is focused on treatment of major risk factors, e.g. hypercholes-
terolemia while in the future direct disease modiﬁ  cation might provide additional beneﬁ  ts.
1,2 However, 
discovery and development of medicines targeting vascular wall disease (and hence not inducing any 
changes of plasma lipids) is complicated by the lack of reliable biomarkers.
2,3 Recent clinical data sug-
gest detrimental cumulative cardiovascular effects of several compounds that improve atherosclerosis 
risk factors.
4,5 Therefore, early indication of pro-atherogenic drug activities would be desired. To date, 
vascular imaging remains the only available option.
3 However, it is expensive and, for some techniques, 
invasive, that limits its application on a large scale.
Is it possible to ﬁ  nd a circulating non-lipid marker that would reﬂ  ect drug-induced changes in ath-
erosclerotic plaques? In the clinic, correlation between markers of inﬂ  ammation and risk of cardiovas-
cular events is established.
6 However, it is unknown whether any of those markers reﬂ  ects drug-induced 
changes in the plaque size.
In ApoE-deﬁ  cient mice, genetically determined hypercholesterolemia leads to development of 
atherosclerotic lesions.
7 Importantly, the lesions develop progressively over time while plasma cho-
lesterol levels stay constant.
8 Therefore, this model provides an opportunity to focus on circulating 
markers that would be associated with the changes in the plaque size but not in plasma cholesterol. 
Apparently, this approach is limited by multiple confounding factors such as age and systemic inﬂ  am-
mation. However, mere separation of plasma cholesterol and vascular drug effects represents the ﬁ  rst 148
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important step in unraveling very complex interac-
tions between drug effects and potential blood 
markers. It has been previously reported that 
angiotensin-II converting enzyme inhibitor 
ramipril(Ram) signiﬁ  cantly reduced atheroscle-
rotic burden ApoE-/- mice and HMG-CoA reduc-
tase inhibitor simvastatin(Sim) paradoxically 
increased lesion size.
9–12 In this paper, we decided 
to exploit this phenomenon and seek circulating 
markers of cholesterol-independent, drug-induced 
vascular changes in ApoE-deﬁ  cient mice. Blood 
and vascular samples were obtained from the same 
animals for histology, blood chemistry, blood RNA 
and protein assessments. The changes in blood 
chemistry, RNA and protein were correlated with 
changes in vascular histology.
Materials and Methods
Animal experiments
All activities were conducted at Taconic 
Biotechnology (1 University Place, Rensselaer NY 
12144). Apolipoprotein E deﬁ  cient (ApoE-/-) mice 
were maintained under murine pathogen free bar-
rier conditions for a duration of 40 weeks with 
continuous health monitoring, and manipulations 
were performed with IACUC approved procedures. 
Animals were fed with Chow diet and maintained 
at 12-hr light and 12-hr dark cycle. Three to four 
animals per cage (3 cages/ treatment group, 10 
animals total) were housed in solid bottom poly-
propylene cages with sterilized bedding. At the age 
of 8 weeks, the mice were either kept on chow diet 
as control group or treated with ramipril or simv-
astatin. Ramipril was dissolved in sterilized drink-
ing water and mice were fed at the dose of 5 
mg/kg/day for 8, 16 and 24 weeks before sacriﬁ  ce. 
Simvastatin was placed in chow diet, mice were 
fed at the dose of 50 mg/kg/day for 8, 16, 24 weeks 
before sacriﬁ  ce. Weekly food and water consump-
tion was recorded for each cage. Two batches of 
dosing experiments were conducted, one batch of 
mice were sacriﬁ  ced for RNA analyses, whereas 
another batch for protein analysis.
Blood was collected via cardiac puncture 
procedure. 250 μl of the whole blood was placed 
directly into the RNA lysis buffer-containing 
tubes provided by the Source Precision Medicine 
and frozen. 200 μl of blood was placed in citrate 
tubes, and plasma was used for protein and lipid 
analysis.
Immediately following the blood collection, 
mice were perfused with saline and then IHC Zink 
ﬁ  xative via left ventricle. Brachiocephalic artery 
was dissected, ﬁ  xed in IHC Zink ﬁ  xative and par-
afﬁ  n embedded.
Histology
10 equally spaced (200 μm) parafﬁ  n cross sections 
of the brachiocephalic artery were stained using 
hematoxylin and eosin. Macrophages and SMC 
were visualized immunohistochemically using 
MAC-2 (Accurate Chemical, Westbury, NY) and 
anti-α-smooth muscle actin antibody (DAKO) 
respectively. The lesion, deﬁ  ned as an area between 
the lumen and internal elastic lamina (IEL) was 
calculated using Image-Pro Plus Version 5.0.1
Blood analysis
Plasma lipids were analyzed on a Hitachi 912 
clinical chemistry analyzer. Total and differential 
blood cell count was performed by the 
LabCorps.
Quantiﬁ  cation of RNA expression. Two hundred 
ﬁ  fty μl of whole blood from each animal were sent 
to Source Precision Medicine (Boulder, CO). 
Expression of blood mRNA was quantiﬁ  ed using 
its proprietary precision technology (a modiﬁ  ed 
ΔΔCT method) with its validated rodent primers 
of ABCA1, CD14, HMOX1, HSPA1A, ILLRN, 
MMP-9, TGFβ1, TLR4, TNFSF5.
Immunoassay of plasma inﬂ  ammation markers. 
Fifty μl of plasma from each animal were sent to 
Rules Based Medicine (Austin, TX) and were 
proﬁ  led using its proprietary multiplex assay plat-
form with multiple analyte panel (MAP) version 
1.5. The MAP contains 59 molecules.
Data analysis
Statistical analyses and pattern analyses were per-
formed on SAS, JMP (SAS Institute, NC), MatLab 
(The MathWorks, MA) and Microsoft Excel.
Results
Atherosclerotic plaques developed 
over time, drug treatment either 
promoted or repressed atherogenesis
At the age of 8 weeks, ApoE-/- mice were treated 
continuously with angiotensin-II converting 149
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enzyme inhibitor ramipril, or HMG-CoA reductase 
inhibitor simvastatin, or by Chow diet alone for 
8, 16 and 24 weeks before sacriﬁ  ce. Figure 1a 
showed that plaque developed steadily from 8 
weeks to 32 weeks in ApoE-/- mice fed with Chow 
diet. Ramipril treatment signiﬁ  cantly reduced the 
size of plaques compared to the Chow fed mice 
in all time points sampled (plaque size reduced 
55.6%, 31.9% and 28.9% in 8, 16, 24 week treat-
ments with p values of 0.005, 0.027 and 0.004, 
respectively. Fig. 1b, 1c and 1d); on the contrary, 
simvastatin increased the atherosclerotic plaques 
compared to the chow fed mice (plaque size 
increased 3.0, 2.48 or 1.8 folds respectively, with 
p values of 0.001). Both treatments had no sig-
niﬁ  cant effects on plasma cholesterol (Fig. 2 and 
Table 1a). Ramipril did not alter the concentration 
of triglycerids, whereas simvastatin signiﬁ  cantly 
reduced the triglyceride concentration (Fig. 2 and 
Table 1b).
Expression of CD14, IL1RN 
and MMP-9 RNA in whole blood 
correlated with the effect of ramipril 
and simvastatin on plaque size
Expression of nine genes was measured in whole 
blood of ApoE -/- mice. These RNA were chosen 
because of available validated rodent primers by 
Source Precision Medicine (Boulder, CO). 
Signiﬁ  cant differences in expression of CD14, 
IL1RN and MMP-9 were observed between 
simvastatin-treated and ramipril-treated ApoE-/- 
mice (Fig. 3 a-c). Compared to those in the Chow-
fed animals, expression of these molecules 
increased in simvastatin-treated animals whose 
plaque sizes signiﬁ  cantly increased over controls. 
In contrast, expression of these molecules decreased 
in ramipril-treated animals (Fig. 3 a-c) whose 
plaque size was signiﬁ  cantly reduced compared to 
the Chow-fed controls. The data suggest that CD14, 
IL1RN and MMP-9 are good biochemical markers 
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Figure 1. Atherosclerotic plaque develops steadily when ApoE-/- mouse ages from 8 to 32 weeks (a). Simvastatin treatment signiﬁ  cantly 
increases plaque formation in ApoE-/- mice, whereas ramipril signiﬁ  cantly decreases plaque formation during 8 week (b), 16 week (c) and 
24 week (d) treatments. Asterisk indicates p-value of 0.05 compared to the control.150
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of drug effects on atherosclerotic lesion size. 
Furthermore, the difference in markers can be 
measured as early as 8 weeks after the beginning 
of drug treatment (Fig. 3a).
Concentration of pro-inﬂ  ammatory 
molecules ﬁ  brinogen, IL-1b, IL-18, 
M-CSF, MMP-9, CD40 and VCAM-1 
in plasma correlated with the effect 
of ramipril and simvastatin 
on plaque size.
Plasma samples were analyzed on multiplex 
assay platform (MAP version 1.5) by Rules Based 
Medicine (Austin, TX). These molecules and 
platform were chosen because of available vali-
dated rodent antibodies by RBM. Out of 59 
molecules analyzed, the concentration of IL-1b, 
IL-18, M-CSF, MMP-9, CD40 and VCAM-1 
increased in simvastatin-treated mice, decreased 
in ramipril-treated mice (Fig. 4, Appendix). Fur-
thermore, the changes of these molecules in 
simvastatin-treated mice comparing to the con-
trols are much more profound than the changes 
in ramipril-treated mice comparing to the con-
trols. The result suggests that these molecules 
are potential biomarkers of drug effects on ath-
erosclerotic lesion size, at least in the case of 
pro-atherogenic changes. The difference in the 
concentration of markers can be measured as 
early as 16 weeks after the beginning of drug 
treatment for IL-1b and MMP-9; all can be mea-
sured at 24 weeks after the beginning of drug 
treatment (Fig. 4).
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Figure 2. Both simvastatin and ramipril treatments do not alter cholesterol level of ApoE-/- mice. Ramapril treatment does not change the 
triglyceride level of ApoE-/- mice, whereas simvastatin treatment signiﬁ  cantly reduces the triglyceride level of ApoE-/- mice. Asterisk indicates 
a statistically signiﬁ  cant difference with p value 0.05 compared to the same age control.
Table 1. Cholesterol (a) and Triglyceride (b) concentration in ApoE-/- Mice.
(a)
Week 8 16 24 32
Control 389.75 + 83.74   599.5 + 122.30 511.32 + 114.87 640.00 + 135.15
Simvastatin 806.18 + 392.78 633.89 + 180.28 516.39 + 119.91
Ramipril 594.25 + 126.12      564 + 131.54 562.00 + 151.51
(b)
Week 8 16 24 32
Control 145.00 + 36.09 302.75 + 128.86 145.53 + 66.58 252.00 + 82.90
Simvastatin 68.82 + 32.19 51.58 + 29.58 51.94 + 19.64
Ramipril 226.50 + 78.46 186.75 + 77.28 192.00 + 89.02151
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No difference in white blood cell number 
among different treatment groups.
To dissect if the difference in gene expression and 
concentration of protein markers were affected by 
the cell number change, number of white blood 
cell from all treatment groups was counted 
(Table 2), no statistically signiﬁ  cant difference 
among the groups were found.
Discussion
In this paper, we have identiﬁ  ed the non-lipid 
circulating biomarkers indicative of both anti- and 
pro-atherogenic drug effects. We treated ApoE-/- mice 
with an ACE inhibitor ramipril and HMG-CoA 
reductase inhibitor simvastatin. Ramipril signiﬁ  -
cantly reduced the size of atherosclerotic plaques 
in brachiocephalic arteries, however simvastatin 
paradoxically stimulated atherogenesis. Both 
effects occurred without changes in plasma cho-
lesterol. We decided to exploit this phenomenon 
and seek circulating markers of cholesterol-
independent, drug-induced vascular changes in 
ApoE-deﬁ  cient mice. Blood and vascular samples 
were obtained from the same animals. In the whole 
blood RNA samples, expression of MMP9, CD14 
and IL-1RN reﬂ  ected pro-and anti-atherogenic 
drug effects. In the plasma, several proteins, e.g. 
IL-1β, IL-18 and MMP9 followed similar trends 
while protein readout was less sensitive than RNA 
analysis.
Ramipril is the only ACE inhibitor that 
is currently approved for the prevention of 
cardiovascular events in high risk patients based 
on the results of the HOPE trial.
13  It was 
demonstrated that in the normotensive patients, 
cardiovascular beneﬁ  ts of ramipril are independent 
of its blood pressure lowering effects.
14  ACE 
inhibitors also do not have lipid-lowering properties. 
Experimental data strongly suggest that these 
effects of ACE inhibitors are mediated by their 
direct anti-inﬂ  ammatory activity that ameliorates 
pro-inﬂ  ammatory signaling of angiotensin II in the 
vasculature.
15 Specifically, ramipril attenuated 
atherosclerosis in ApoE-/- mice in a blood pressure- 
and cholesterol-independent manner
10 while 
preventing macrophage activation.
9 In agreement 
with these data, we demonstrated that ramipril 
treatment signiﬁ  cantly reduced atherosclerotic 
plaque size in ApoE-/- mice. Moreover, we have 
identiﬁ  ed several blood markers that have changed 
accordingly.
Figure 3. Expression changes of whole blood RNA from simvastatin 
or ramipril treated ApoE-/- mice at the age of 16 weeks (a), 24 weeks 
(b) and 32 weeks (c). Y-axis is the fold change compared to the 
control group (1 means no change). Note the direction and robust-
ness of changes of CD14, IL1RN and MMP9 over treatment times. 
The mice were initially fed with the Chow diet for 8 weeks before 
subsequent drug treatments. Asterisk indicates a statically signiﬁ  cant 
difference with p value  0.05 between simvastatin and ramipril 
groups.
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Statins, including simvastatin, have unequivocal 
effect on the reduction of cardiovascular and all-
cause mortality, and this is likely due to the reduction 
in cholesterol.
16 However, the data on statin efﬁ  cacy 
in ApoE-/- mice are controversial.
17 Sparrow et al. 
reported anti-inﬂ  ammatory and anti-atherosclerotic 
activities of simvastatin exerted without any changes 
of plasma lipids.
18 Short-term anti-inﬂ  ammatory 
effects are also documented in the study of Scalia 
et al.
19 However, several groups reported signiﬁ  cant 
elevation of plasma cholesterol associated with 
increased atherosclerotic burden
20 and plaque size
12 
in the mice with spontaneous atherosclerosis or 
intimal hyperplasia induced by mechanical injury 
of the artery.
11 It is suggested that paradoxical plasma 
cholesterol elevation could be driven by formation 
of cholesterol-rich remnants in apoE-/- mice.
21 
Overall, pro-atherogenic effects of simvastatin in 
these studies are assumed to be the consequence of 
cholesterol elevation.
Our results, however, demonstrated an increase 
in plaque size without signiﬁ  cant plasma cholesterol 
elevation. That suggests potential direct 
pro-atherogenic (likely pro-inﬂ  ammatory) vascular 
effects of the drug in this animal model. Albeit coun-
ter-intuitive, this mechanism is supported by the data 
obtained in cultured human monocyte-derived mac-
rophages. Kiener et al. reported that simvastatin 
stimulated production of MCP-1, IL-8, IL-1β and 
TNF-α.
22 Lindholm and Nilsson recently 
demonstrated that simvastatin stimulated IL-1β 
secretion.
23 Simvastatin also exerted pro-inﬂ  ammatory 
effects in a mouse model of peritonitits.
22 Recently, 
direct pro-apoptotic effects of simvastatin in human 
endothelial cells have been demonstrated.
24 Thus, it 
is plausible that under certain experimental 
circumstances simvastatin may exhibit pro-
inﬂ  ammatory properties that in the clinic either do 
not occur or are counterbalanced by profound lipid 
lowering thereby providing ultimate therapeutic 
beneﬁ  ts. In the current study, we have not attempted 
detailed mechanistic analysis of simvastatin activity 
in ApoE-/- mice. Rather, we capitalized on the obser-
vation that its pro-atherogenic effects, regardless the 
mechanism, were associated with an upsurge of 
several blood inﬂ  ammation markers.
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Figure 4. The plasma concentration of CD14, ﬁ  brinogen, IL1β, IL18, MCSF, MMP-9 and VCAM-1 changes in ApoE-/- mice treated with 
simvastatin or ramipril. In general, the concentrations of these markers increase in mice treated with simvastatin, whereas they decrease in 
mice treated with ramipril. LDD—Least Detectable Dose as determined by Rules Based Medicine (Austin, TX), red line—simvastatin treat-
ment, green line—ramipril treatment, blue line—the Chow fed control. Asterisk indicates a statically signiﬁ  cant difference with p value  0.05 
between simvastatin / or ramipril and control groups.153
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Taken together, ramipril and simvastatin arms 
of the study demonstrated that the same set of 
circulating markers responded in coordinated 
manner to both anti- and pro-atherogenic, lipid-
independent drug effects. Exact mechanistic links 
between vascular effects of these drugs and their 
effects on the circulating markers of inﬂ  ammation 
are unknown. Several possibilities and 
combinations thereof exist. Moreover, the genesis 
of blood RNA and protein markers is likely to be 
different.
Whole blood RNA represents gene expression 
of various circulating cell populations, predomi-
nantly white blood cells, although it is impossible 
to exclude a contribution of red blood cells and 
platelets. White blood cell count per se may be 
associated with atherosclerosis.
25 That phenomenon 
alone might be responsible for apparent changes in 
gene expression. Our data though demonstrated no 
drug effect on the white blood cell number. How-
ever, enrichment of speciﬁ  c leukocyte types may 
still account for the RNA changes. It has been 
shown that the rise in monocyte count is associated 
with plaque formation in humans
26 and in the West-
ern diet-fed ApoE-/- mice.
27 In the current study, 
we have not detected any signiﬁ  cant changes in 
monocyte numbers. However, more detailed 
analysis of monocyte sub-populations is granted. 
Thus, our data suggest that both ramipril and sim-
vastatin could exert effects on the gene expression 
rather than affect the cell number. It remains unclear 
whether the drugs directly affected gene expression 
in circulating cells or, alternatively, blood RNA 
changes were secondary to the vascular wall effects. 
This is a fundamental and yet unanswered question 
that demands future in-depth research. The answer 
will determine how blood RNA changes will be 
positioned, i.e. as pharmacodynamic markers of 
drug activity or as circulating markers reﬂ  ecting 
biology of atherosclerotic plaques.
Specific tissue sources of plasma protein 
changes are even less clear. MMPs and interleukins 
(the proteins that, according to our data, seem to 
be sensitive to ramipril and simvastatin treatment) 
could originate, among other tissues, in the liver, 
adipose tissue or atherosclerotic plaques them-
selves. Regardless the exact origin, however, they 
have potential to become useful markers assuming 
that described effects can be extended to the other 
drugs capable of modifying vascular wall.
Although only limited set of genes and proteins 
was analyzed, it is tempting to speculate about 
coordinated nature of identiﬁ  ed changes. Notice-
able MMP9 dynamics (downward with ramipril 
and upward with simvastatin) was detected both at 
the level of blood RNA and plasma protein, sug-
gestive of the multiple tissues response. MMP9 
protein levels in the lesions and in plasma are asso-
ciated with plaque development and rupture in 
human and mouse atherosclerosis.
28–30 Extending 
that knowledge to circulating cell RNA (far more 
sensitive readout in this study) and demonstration 
of drug effects further validates this marker and 
potentially increases it’s utility. CD14 gene up-
regulation in circulating leukocytes is consistent 
with emerging role of innate immunity in 
atherosclerosis.
1 It is likely that plasma IL1 protein 
elevation reﬂ  ects one of the downstream effects of 
activated innate immunity signaling. IL-1RN up-
regulation, anti-inﬂ  ammatory by nature, may indi-
cate a negative compensatory feedback response to 
IL-1 elevation.
31 In this case, an anti-inﬂ  ammatory 
gene may be paradoxically portrayed as a sensitive 
marker of inﬂ  ammation and/or atherosclerosis.
We had also attempted to use whole blood pro-
teomic approach (data not shown). However, whole 
blood proteomics has yet to provide discriminatory 
power that was necessary to identify the changes 
in inﬂ  ammatory protein molecules. A detailed 
report on comparing the whole blood shotgun 
proteomics vs. targeted proteomics approaches will 
be presented elsewhere.
In aggregate, our data suggest that a set of 
inflammation-related markers, both at the level 
of circulating leukocyte activation and systemic 
response may be indicative of pro- and anti-atherogenic 
drug effects. Current study represents the ﬁ  rst step 
Table 2. White Blood Cell Count From ApoE-/- Mice*.
Week Treatment WBC (10^3/μL)
32 Control 3.08 ± 0.70
32 Simvastatin 3.35 ± 1.66
32 Ramipril 2.67 ± 0.98
24 Control 2.96 ± 0.66
24 Simvastatin 1.69 ± 0.53
24 Ramipril 2.70 ± 0.63
16 Control 1.85 ± 0.84
16 Simvastatin 1.97 ± 0.15
16 Ramipril NA
8 Control 2.05 ± 0.92
*There is no statistical signiﬁ  cant difference among groups.154
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towards identiﬁ  cation of circulating markers reﬂ  ecting 
lipid-independent, disease-modifying drug effects. 
The number of compounds with different mechanism 
of action as well as candidate genes and proteins needs 
to be extended. If further validated, presented approach 
might be useful in early prediction of vascular efﬁ  cacy 
and/or potential vascular toxicity of investigational 
drugs.
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Appendix
Multi-analyte proﬁ  le of plasma protein from apoE-/- mice.
Marker Treatment1
a Treatment2
b Conc_1 Conc_2 Fold change p value LDD
c
CD40 16wRam 16wCon 82.81 ± 22.949 66.74 ± 19.237 1.24 0.1284 12
CD40 16wSim 16wCon 113.84 ± 42.431 66.74 ± 19.237 1.71 0.0001 12
CD40 24wRam 24wCon 56.96 ± 8.867 62.41 ± 19.322 −1.1 0.6445 12
CD40 24wSim 24wCon 119.97 ± 30.577 62.41 ± 19.322 1.92 0 12
CD40 32wRam 32wCon 42.5 ± 12.481 59.58 ± 19.073 −1.4 0.1159 12
CD40 32wSim 32wCon 95.33 ± 33.306 59.58 ± 19.073 1.6 0.0033 12
CD40 16wCon 8wCon 66.74 ± 19.237 59.81 ± 9.015 1.12 0.5208 12
CD40 16wRam 8wCon 82.81 ± 22.949 59.81 ± 9.015 1.38 0.0354 12
CD40 16wSim 8wCon 113.84 ± 42.431 59.81 ± 9.015 1.9 0 12
CD40 24wCon 8wCon 62.41 ± 19.322 59.81 ± 9.015 1.04 0.8257 12
CD40 24wRam 8wCon 56.96 ± 8.867 59.81 ± 9.015 −1.1 0.7963 12
CD40 24wSim 8wCon 119.97 ± 30.577 59.81 ± 9.015 2.01 0 12
CD40 32wCon 8wCon 59.58 ± 19.073 59.81 ± 9.015 −1 0.9832 12
CD40 32wRam 8wCon 42.5 ± 12.481 59.81 ± 9.015 −1.4 0.1111 12
CD40 32wSim 8wCon 95.33 ± 33.306 59.81 ± 9.015 1.59 0.0035 12
Fibrinogen 16wRam 16wCon 3358 ± 949.18 3810 ± 500.58 −1.1 0.398 12
Fibrinogen 16wSim 16wCon 3615 ± 496.47 3810 ± 500.58 −1.1 0.7305 12
Fibrinogen 24wRam 24wCon 4037.78 ± 646.43 4596.67 ± 1647.3 −1.1 0.3218 12
Fibrinogen 24wSim 24wCon 3408.89 ± 744.32 4596.67 ± 1647.3 −1.3 0.0372 12
Fibrinogen 32wRam 32wCon 3614 ± 648.08 4371 ± 971.3 −1.2 0.1585 12
Fibrinogen 32wSim 32wCon 5494.29 ± 3060.4 4371 ± 971.3 1.26 0.0588 12
Fibrinogen 16wCon 8wCon 3810 ± 500.58 2553.33 ± 754.4 1.49 0.0241 12
Fibrinogen 16wRam 8wCon 3358 ± 949.18 2553.33 ± 754.4 1.32 0.1448 12
Fibrinogen 16wSim 8wCon 3615 ± 496.47 2553.33 ± 754.4 1.42 0.0699 12
Fibrinogen 24wCon 8wCon 4596.67 ± 1647.3 2553.33 ± 754.4 1.8 0.0005 12
Fibrinogen 24wRam 8wCon 4037.78 ± 646.43 2553.33 ± 754.4 1.58 0.0097 12
Fibrinogen 24wSim 8wCon 3408.89 ± 744.32 2553.33 ± 754.4 1.34 0.1309 12
Fibrinogen 32wCon 8wCon 4371 ± 971.3 2553.33 ± 754.4 1.71 0.0013 12
Fibrinogen 32wRam 8wCon 3614 ± 648.08 2553.33 ± 754.4 1.42 0.0558 12
Fibrinogen 32wSim 8wCon 5494.29 ± 3060.4 2553.33 ± 754.4 2.15 0 12
IL_18 16wRam 16wCon 0.85 ± 0.122 0.84 ± 0.065 1.01 0.8771 0.67
IL_18 16wSim 16wCon 1.18 ± 0.155 0.84 ± 0.065 1.4 0.0001 0.67
IL_18 24wRam 24wCon 0.88 ± 0.161 0.94 ± 0.254 −1.1 0.4334 0.67
IL_18 24wSim 24wCon 1.18 ± 0.218 0.94 ± 0.254 1.26 0.0027 0.67
IL_18 32wRam 32wCon 0.8 ± 0.161 0.95 ± 0.21 −1.2 0.0475 0.67
IL_18 32wSim 32wCon 1.37 ± 0.103 0.95 ± 0.21 1.45 0 0.67
IL_18 16wCon 8wCon 0.84 ± 0.065 0.78 ± 0.079 1.07 0.4435 0.67
IL_18 16wRam 8wCon 0.85 ± 0.122 0.78 ± 0.079 1.09 0.3598 0.67
IL_18 16wSim 8wCon 1.18 ± 0.155 0.78 ± 0.079 1.5 0 0.67
IL_18 24wCon 8wCon 0.94 ± 0.254 0.78 ± 0.079 1.2 0.0498 0.67
IL_18 24wRam 8wCon 0.88 ± 0.161 0.78 ± 0.079 1.12 0.2319 0.67
IL_18 24wSim 8wCon 1.18 ± 0.218 0.78 ± 0.079 1.5 0 0.67
IL_18 32wCon 8wCon 0.95 ± 0.21 0.78 ± 0.079 1.21 0.0317 0.67
IL_18 32wRam 8wCon 0.8 ± 0.161 0.78 ± 0.079 1.02 0.8209 0.67
IL_18 32wSim 8wCon 1.37 ± 0.103 0.78 ± 0.079 1.75 0 0.67156
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IL_1beta 16wRam 16wCon 0.44 ± 0.055 0.4 ± 0.089 1.11 0.3863 0.45
IL_1beta 16wSim 16wCon 0.51 ± 0.175 0.4 ± 0.089 1.27 0.048 0.45
IL_1beta 24wRam 24wCon 0.42 ± 0.118 0.5 ± 0.105 −1.2 0.1166 0.45
IL_1beta 24wSim 24wCon 0.61 ± 0.093 0.5 ± 0.105 1.21 0.0519 0.45
IL_1beta 32wRam 32wCon 0.37 ± 0.111 0.54 ± 0.12 −1.4 0.002 0.45
IL_1beta 32wSim 32wCon 0.66 ± 0.042 0.54 ± 0.12 1.23 0.026 0.45
IL_1beta 16wCon 8wCon 0.4 ± 0.089 0.35 ± 0.156 1.13 0.3782 0.45
IL_1beta 16wRam 8wCon 0.44 ± 0.055 0.35 ± 0.156 1.26 0.0916 0.45
IL_1beta 16wSim 8wCon 0.51 ± 0.175 0.35 ± 0.156 1.44 0.0075 0.45
IL_1beta 24wCon 8wCon 0.5 ± 0.105 0.35 ± 0.156 1.42 0.0077 0.45
IL_1beta 24wRam 8wCon 0.42 ± 0.118 0.35 ± 0.156 1.18 0.236 0.45
IL_1beta 24wSim 8wCon 0.61 ± 0.093 0.35 ± 0.156 1.72 0 0.45
IL_1beta 32wCon 8wCon 0.54 ± 0.12 0.35 ± 0.156 1.52 0.0009 0.45
IL_1beta 32wRam 8wCon 0.37 ± 0.111 0.35 ± 0.156 1.06 0.6756 0.45
IL_1beta 32wSim 8wCon 0.66 ± 0.042 0.35 ± 0.156 1.88 0 0.45
MMP_9 16wRam 16wCon 6.33 ± 1.749 5.43 ± 1.606 1.17 0.4204 10
MMP_9 16wSim 16wCon 11.7 ± 2.561 5.43 ± 1.606 2.15 0 10
MMP_9 24wRam 24wCon 6.61 ± 3.155 8.79 ± 3.575 −1.3 0.0669 10
MMP_9 24wSim 24wCon 13.36 ± 2.711 8.79 ± 3.575 1.52 0.0002 10
MMP_9 32wRam 32wCon 7.01 ± 1.989 9.44 ± 2.785 −1.3 0.0316 10
MMP_9 32wSim 32wCon 14.57 ± 2.769 9.44 ± 2.785 1.54 0.0001 10
MMP_9 16wCon 8wCon 5.43 ± 1.606 7.55 ± 1.138 −1.4 0.0668 10
MMP_9 16wRam 8wCon 6.33 ± 1.749 7.55 ± 1.138 −1.2 0.2879 10
MMP_9 16wSim 8wCon 11.7 ± 2.561 7.55 ± 1.138 1.55 0.0009 10
MMP_9 24wCon 8wCon 8.79 ± 3.575 7.55 ± 1.138 1.16 0.2941 10
MMP_9 24wRam 8wCon 6.61 ± 3.155 7.55 ± 1.138 −1.1 0.4252 10
MMP_9 24wSim 8wCon 13.36 ± 2.711 7.55 ± 1.138 1.77 0 10
MMP_9 32wCon 8wCon 9.44 ± 2.785 7.55 ± 1.138 1.25 0.1023 10
MMP_9 32wRam 8wCon 7.01 ± 1.989 7.55 ± 1.138 −1.1 0.6352 10
MMP_9 32wSim 8wCon 14.57 ± 2.769 7.55 ± 1.138 1.93 0 10
M_CSF 16wRam 16wCon 3.8 ± 0.362 3.77 ± 0.327 1.01 0.8943 0.018
M_CSF 16wSim 16wCon 4.86 ± 0.573 3.77 ± 0.327 1.29 0.0002 0.018
M_CSF 24wRam 24wCon 3.59 ± 0.456 3.88 ± 1.067 −1.1 0.2943 0.018
M_CSF 24wSim 24wCon 4.76 ± 0.595 3.88 ± 1.067 1.23 0.0019 0.018
M_CSF 32wRam 32wCon 3.31 ± 0.699 3.85 ± 0.611 −1.2 0.0449 0.018
M_CSF 32wSim 32wCon 4.79 ± 0.467 3.85 ± 0.611 1.25 0.0016 0.018
M_CSF 16wCon 8wCon 3.77 ± 0.327 2.93 ± 0.322 1.29 0.0026 0.018
M_CSF 16wRam 8wCon 3.8 ± 0.362 2.93 ± 0.322 1.3 0.0017 0.018
M_CSF 16wSim 8wCon 4.86 ± 0.573 2.93 ± 0.322 1.66 0 0.018
M_CSF 24wCon 8wCon 3.88 ± 1.067 2.93 ± 0.322 1.32 0.001 0.018
M_CSF 24wRam 8wCon 3.59 ± 0.456 2.93 ± 0.322 1.22 0.0203 0.018
M_CSF 24wSim 8wCon 4.76 ± 0.595 2.93 ± 0.322 1.63 0 0.018
M_CSF 32wCon 8wCon 3.85 ± 0.611 2.93 ± 0.322 1.31 0.0011 0.018
M_CSF 32wRam 8wCon 3.31 ± 0.699 2.93 ± 0.322 1.13 0.1617 0.018
M_CSF 32wSim 8wCon 4.79 ± 0.467 2.93 ± 0.322 1.64 0 0.018
VCAM_1 16wRam 16wCon 1151.8 ± 194.51 1141 ± 117.99 1.01 0.9075 0.95
VCAM_1 16wSim 16wCon 1692.5 ± 176.7 1141 ± 117.99 1.48 0 0.95
(Continued)
Marker Treatment1
a Treatment2
b Conc_1 Conc_2 Fold change p value LDD
c
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VCAM_1 24wRam 24wCon 1296.67 ± 188.75 1296.67 ± 301.04 0 1 0.95
VCAM_1 24wSim 24wCon 1956.67 ± 197.23 1296.67 ± 301.04 1.51 0 0.95
VCAM_1 32wRam 32wCon 1252.6 ± 186.93 1449 ± 243.33  −1.2 0.0371 0.95
VCAM_1 32wSim 32wCon 1891.43 ± 297.96 1449 ± 243.33 1.31 0 0.95
VCAM_1 16wCon 8wCon 1141 ± 117.99 763.22 ± 107.73 1.49 0.0002 0.95
VCAM_1 16wRam 8wCon 1151.8 ± 194.51 763.22 ± 107.73 1.51 0.0001 0.95
VCAM_1 16wSim 8wCon 1692.5 ± 176.7 763.22 ± 107.73 2.22 0 0.95
VCAM_1 24wCon 8wCon 1296.67 ± 301.04 763.22 ± 107.73 1.7 0 0.95
VCAM_1 24wRam 8wCon 1296.67 ± 188.75 763.22 ± 107.73 1.7 0 0.95
VCAM_1 24wSim 8wCon 1956.67 ± 197.23 763.22 ± 107.73 2.56 0 0.95
VCAM_1 32wCon 8wCon 1449 ± 243.33 763.22 ± 107.73 1.9 0 0.95
VCAM_1 32wRam 8wCon 1252.6 ± 186.93 763.22 ± 107.73 1.64 0 0.95
VCAM_1 32wSim 8wCon 1891.43 + 297.96 763.22 ± 107.73 2.48 0 0.95
a,b: Week and treatment. For example, 32wSim indicates simvastatin treated animals at the age of 32 weeks. Ram –Ramipril, Con – control. 
cLeast detectable dose.
(Continued)
Marker Treatment1
a Treatment2
b Conc_1 Conc_2 Fold change p value LDD
c